{"nctId":"NCT01821391","briefTitle":"Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses","startDateStruct":{"date":"2013-07"},"conditions":["Actinic Keratoses"],"count":131,"armGroups":[{"label":"NDL-PDT/c-PDT","type":"EXPERIMENTAL","interventionNames":["Drug: NDL-PDT","Drug: c-PDT"]},{"label":"NDL-PDT/placebo c-PDT","type":"EXPERIMENTAL","interventionNames":["Drug: NDL-PDT","Drug: placebo c-PDT"]}],"interventions":[{"name":"NDL-PDT","otherNames":["Metvix NDL-PDT"]},{"name":"c-PDT","otherNames":["Metvix c-PDT"]},{"name":"placebo c-PDT","otherNames":["Metvix placebo c-PDT"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of mild (Grade 1) and/or moderate (Grade 2) AKs on the face or the scalp on treated areas\n* Subject with two symmetrical treated areas half scalps or two half faces excluding ears, chin, bridge of the nose, eyelids and lips inside the vermillion border): no more than a twofold difference in terms of total number of lesions between the two TAs\n\nExclusion Criteria:\n\n* Subject with clinical diagnosis of at least one severe (Grade 3) AK on treated areas\n* Subject with pigmented AK on the treated areas\n* Immuno-compromised Subject for idiopathic, disease specific or therapeutic reasons\n* Subject with porphyria,","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage (%) Change From Baseline in Total Lesion Complete Response at Week 12 in Group 1","description":"The lesion complete response rate was defined as the percentage of pre-existing and treated lesions at Baseline that were assessed as clear (complete disappearance of the lesion, visually and by palpation) at Week 12. New lesions or the lesions in non-complete response were not not considered in the lesion response assessment. This outcome measure was analyzed as an intra-individual comparison between Metvix NDL-PDT on one side of the face/scalp and Metvix vehicle cream (placebo) c-PDT on the contralateral side (Group I).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.4","spread":"27.7"},{"groupId":"OG001","value":"71.5","spread":"27.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":131},"commonTop":["Erythema","Pruritus","Scab","Skin burning sensation","Pain of skin"]}}}